[
    [
        {
            "time": "2018-01-02",
            "original_text": "Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "Congress",
                    "Drug Pricing"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "The patent system ‘keeps American drug prices so high’",
            "features": {
                "keywords": [
                    "patent system",
                    "American drug prices"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The patent system ‘keeps American drug prices so high’",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Senate panel grills pharma CEO over executive bonuses. Calls tie to sales of AbbVie blockbuster drug Humira 'problematic'",
            "features": {
                "keywords": [
                    "Senate panel",
                    "pharma CEO",
                    "executive bonuses",
                    "AbbVie",
                    "Humira"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Senate panel grills pharma CEO over executive bonuses. Calls tie to sales of AbbVie blockbuster drug Humira 'problematic'",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Voyager Therapeutics, Inc. (VYGR) Q4 2018 Earnings Conference Call Transcript",
            "features": {
                "keywords": [
                    "Voyager Therapeutics",
                    "Q4 2018 Earnings",
                    "Conference Call"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Voyager Therapeutics, Inc. (VYGR) Q4 2018 Earnings Conference Call Transcript",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Senators Press Drug-Company Executives Over Prices",
            "features": {
                "keywords": [
                    "Senators",
                    "Drug-Company Executives",
                    "Prices"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Senators Press Drug-Company Executives Over Prices",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]